Message from John Leonard, MD Program Director
“As we begin 2015, I am struck by the remarkable progress that has been made for patients with lymphoma in 2014.”
Click here for the full article.
Lymphoma Program Highlights
We believe that the future of oncology lies in targeted, non-chemotherapy drugs. During the 56th annual meeting of the American Society of Hematology (ASH), researchers and physicians in our program were involved in whole or in part with the presentation of 41 abstracts. The following are selected summaries regarding our work to understand why patients with DLBCL have different responses to therapy. A full list of our ASH abstracts can be found here.
Virtual B-cell Lymphoma Model Could Help Predict Effective Combination Therapy
Dr. Olivier Elemento
DLBCL Exosomes and their Potential for a New Targeted Therapy
Dr. Rita Shaknovich
DNA Methylation can Predict Disease Progression Time of DLBCL
Dr. Yanwen Jiang
Clinical Trial Spotlight
This is a select list of our open trials. Currently there are over 30 open trials for various lymphomas at WCMC. A complete listing of our offerings can be found at: http://cornellmedicine.com/trials/
This clinical trial is for men and women with previously treated diffuse large B-cell lymphoma (DLBCL). For patients who are not cured with front-line therapy, DLBCL is a very difficult disease to manage. This is a randomized, two-arm, multicenter, open-label phase 2b study of selinexor at a high dose or a low dose combined with low dose dexamethasone given orally to patients with relapsed/refractory DLBCL who have no therapeutic options of demonstrated clinical benefit.
Key eligibility
* Men and women age 18 and older.
* Pathologically confirmed relapsed and/or refractory DLBCL.
* Documented evidence of disease progression after the most recently administered chemotherapy regimen.
* Patients must have received at least 2 but no more than 4 prior multi-agent therapies.
This clinical trial is for men and women with high-risk previously untreated diffuse large B-cell lymphoma (DLBCL) or grade 3B follicular lymphoma. The goal of the current study is to identify a dose and schedule of CC-486 that can be safely administered with R-CHOP. Study treatment consists of six 21-day cycles of standard-of-care R-CHOP. The first cycle is preceded by a 7-day priming course of CC-486 starting 7 days before the start of R-CHOP. R-CHOP is administered on Days 1 to 5 followed by CC-486 on Days 8 to 21 for Cycles 1 to 5.
Key eligibility
* Men and women age 18 and older.
* Able to adhere to the study visit schedule and other protocol requirements.
* Histologically confirmed previously untreated DLBCL or Grade 3B FL.
* No prior anti-lymphoma therapy.
* Have adequate bone marrow function.
Patient Experience
“At Weill Cornell Medical College we have the privilege of helping thousands of people every year. Everyone has a story and we would like to highlight some of those stories here. For this issue Jasmine Sanabria answered some questions about her response to her diagnosis with follicular lymphoma.”
New Developments in Lymphoma 